Apogee Therapeutics Has Initiated Dosing Of Healthy Volunteers In Its First Clinical Trial For APG990, A Novel, Subcutaneous Half-life Extended Monoclonal Antibody Targeting OX40L, Which Is Being Developed Initially For Atopic Dermatitis
Portfolio Pulse from Benzinga Newsdesk
Apogee Therapeutics has started dosing healthy volunteers in its first clinical trial for APG990, a novel subcutaneous half-life extended monoclonal antibody targeting OX40L, initially developed for atopic dermatitis.
August 19, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apogee Therapeutics has initiated dosing in its first clinical trial for APG990, a novel monoclonal antibody targeting OX40L for atopic dermatitis.
The initiation of dosing in a clinical trial is a significant milestone for a biotech company. This news is likely to positively impact Apogee Therapeutics' stock price in the short term as it demonstrates progress in their drug development pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100